Corey Davis
Stock Analyst
(n/a)
# 4,648
Out of 4,649 analysts
18
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $32 → $26 | $1.39 | +1,770.50% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $1.32 | +3,687.88% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $13.83 | +189.33% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $6.06 | +2,705.28% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $4.89 | +309.00% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $17.67 | +182.97% | 3 | Jan 19, 2018 | |
| CARA Cara Therapeutics | Initiates: Buy | $27 | $0.31 | +8,573.31% | 1 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $111.55 | +29.09% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $32 → $26
Current: $1.39
Upside: +1,770.50%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $1.32
Upside: +3,687.88%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $13.83
Upside: +189.33%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $6.06
Upside: +2,705.28%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $4.89
Upside: +309.00%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $17.67
Upside: +182.97%
Cara Therapeutics
Jan 19, 2018
Initiates: Buy
Price Target: $27
Current: $0.31
Upside: +8,573.31%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $111.55
Upside: +29.09%